Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiac Imaging Parameters: A Systematic Review and Meta-analysis of Randomized Controlled Trials
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Recent studies have shown that sodium/glucose cotransporter 2 (SGLT2) inhibitors might exert favourable changes on cardiac parameters as observed on cardiovascular imaging. We conducted a systematic review and meta-analysis to determine the effects of SGLT2 inhibitors on cardiac imaging parameters. Four electronic databases (PubMed, Embase, Cochrane, Scopus) were searched for studies in which the effects of SGLT2 inhibitors on cardiac imaging parameters were examined. Studies in which a population was administered SGLT2 inhibitors and analysed by echocardiography and/or cardiac magnetic resonance (CMR) imaging were included. Random-effects pair-wise meta-analysis models were utilized to summarize the studies. A total of 11 randomized controlled trials was included with a combined cohort of 910 patients. Comparing patients receiving SGLT2 inhibitors with subjects receiving placebo, the mean change in CMR-measured left ventricular mass (LVM) was −3.87 g (95% confidence interval [CI], −7.77 to 0.04), that in left ventricular end-systolic volume (LVESV) was −5.96 mL (95% CI, −10.52 to −1.41) for combined LVESV outcomes, that in left atrial volume index (LAVi) was −1.78 mL/m2 (95% CI, −3.01 to −0.55) for combined LAVi outcomes, and that in echocardiography-measured E/e′ was −0.73 (95% CI, −1.43 to −0.03). Between-group differences were not observed in LVM and LVESV after indexation. The only between-group difference that persisted was for LAVi. Treatment with SGLT2 inhibitors resulted in reduction in LAVi and E/e′ on imaging, indicating they might have an effect on outcomes associated with LV diastolic function.
Abstract
Recent studies have shown that sodium/glucose cotransporter 2 (SGLT2) inhibitors might exert favourable changes on cardiac parameters as observed on cardiovascular imaging. We conducted a systematic review and meta-analysis to determine the effects of SGLT2 inhibitors on cardiac imaging parameters. Four electronic databases (PubMed, Embase, Cochrane, Scopus) were searched for studies in which the effects of SGLT2 inhibitors on cardiac imaging parameters were examined. Studies in which a population was administered SGLT2 inhibitors and analysed by echocardiography and/or cardiac magnetic resonance (CMR) imaging were included. Random-effects pair-wise meta-analysis models were utilized to summarize the studies. A total of 11 randomized controlled trials was included with a combined cohort of 910 patients. Comparing patients receiving SGLT2 inhibitors with subjects receiving placebo, the mean change in CMR-measured left ventricular mass (LVM) was −3.87 g (95% confidence interval [CI], −7.77 to 0.04), that in left ventricular end-systolic volume (LVESV) was −5.96 mL (95% CI, −10.52 to −1.41) for combined LVESV outcomes, that in left atrial volume index (LAVi) was −1.78 mL/m2 (95% CI, −3.01 to −0.55) for combined LAVi outcomes, and that in echocardiography-measured E/e′ was −0.73 (95% CI, −1.43 to −0.03). Between-group differences were not observed in LVM and LVESV after indexation. The only between-group difference that persisted was for LAVi. Treatment with SGLT2 inhibitors resulted in reduction in LAVi and E/e′ on imaging, indicating they might have an effect on outcomes associated with LV diastolic function.
참고문헌 (38)
- Blankstein R, "Cardiology patient page. Introduction to noninvasive cardiac imaging", Circulation, 125, pp.e267~e271 (2012)
- Cavalcante JL, "Cardiovascular magnetic resonance imaging for structural and valvular heart disease interventions", JACC Cardiovasc Interv, 9, pp.399~425 (2016)
- Shibayama K, "Clinical use of echocardiography in structural heart disease", Gen Thorac Cardiovasc Surg, 64, pp.365~372 (2016)
- Teo YH, "Effects of sodium", glucose cotransporter 2(SGLT2)inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus : a systematic review and meta-analysis of randomized-controlled trials, 2021, pp.10, e019463~
- Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2diabetes", N Engl J Med, 373, pp.2117~2128 (2015)
- Lee MM, "Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction(SUGAR-DM-HF)", Circulation, 143, pp.516~525 (2021)
- Verma S, "Effect of empagliflozin on left ventricular mass in patients with type 2diabetes mellitus and coronary artery disease : the EMPA-HEART CardioLink-6 randomized clinical trial", Circulation, 140, pp.1693~1702 (2019)
- Page MJ, "The PRISMA 2020 statement : an updated guideline for reporting systematic reviews", BMJ, 372, pp.n71~ (2021)
- Higgins JP, "The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials", BMJ, 343, pp.d5928~ (2011)
- Schünemann H, "Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach" (2013), The GRADE Working Group
- The Cochrane Collaboration, "ReviewManager(RevMan). Version 5. 4", The Cochrane Collaboration, ~ (2020)
- Higgins JP, "Cochrane Handbook for Systematic Reviews of Interventions" (2019), The Cochrane Collaboration;
- Furukawa TA, "Imputing missing standard deviations in meta-analyses can provide accurate results", J Clin Epidemiol, 59, pp.7~10 (2006)
- Wan X, "Estimating the sample mean and standard deviation from the sample size, median, range and", or interquartile range, 2014, pp.14, 135~
- Santos-Gallego CG, "Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction", J Am Coll Cardiol, 77, pp.243~255 (2021)
- Chaimani A, "Cochrane Handbook for Systematic Reviews of Interventions, Version 6.1" (2020), The Cochrane Collaboration;
- Brown AJ, "A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes : the DAPA-LVH trial", Eur Heart J, 41, pp.3421~3432 (2020)
- Oldgren J, "Effects of 6 weeks of treatment with dapagliflozin, a sodiumglucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2diabetes : a randomized, placebo-controlled, exploratory study", Diabetes Obes Metab, 23, pp.1505~1517 (2021)
- Shim CY, "Randomized, controlled trial to evaluate the effect of dapagliflozin on left ventricular diastolic function in patients with type 2 diabetes mellitus : the IDDIA trial", Circulation, 143, pp.510~512 (2021)
- Singh JS, "Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure : the REFORM trial", Diabetes Care, 43, pp.1356~1359 (2020)
- de Boer RA, "Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure", Br J Clin Pharmacol, 86, pp.1346~1356 (2020)
- Omar M, "Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction : a substudy of the empire HF randomized clinical trial", JAMA Cardiol, 6, pp.836~840 (2021)
- Rau M, "Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes : a randomized controlled study", Cardiovasc Diabetol, 20, pp.6~ (2021)
- EickhoffMK, "Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria-a double blind randomized placebo-controlled crossover trial", J Diabetes Complications, 34, pp.107590~ (2020)
- Sattar N, "SGLT2 Inhibition and cardiovascular events : why did EMPA-REG outcomes surprise and what were the likely mechanisms?", Diabetologia, 59, pp.1333~1339 (2016)
- Chilton R, "Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes", Diabetes Obes Metab, 17, pp.1180~1193 (2015)
- Ferrannini E, "CV protection in the EMPA-REG OUTCOME trial : a"Thrifty Substrate"hypothesis", Diabetes Care, 39, pp.1108~1114 (2016)
- Iannantuoni F, "The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes", J Clin Med, 8, pp.1814~ (2019)
- Heerspink HJ, "Canagliflozin reduces inflammation and fibrosis biomarkers : a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease", Diabetologia, 62, pp.1154~1166 (2019)
- Leng W, "The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3inflammasome axis in steatohepatitis with diabetes mellitus", Ann Transl Med, 7, pp.429~ (2019)
- GBD 2017 Disease, "Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017 : a systematic analysis for the Global Burden of Disease Study 2017", Lancet, 392, pp.1789~1858 (2018)
- Kane GC, "Progression of left ventricular diastolic dysfunction and risk of heart failure", JAMA, 306, pp.856~863 (2011)
- Little WC, "Echocardiographic evaluation of diastolic function can be used to guide clinical care", Circulation, 120, pp.802~809 (2009)
- Tamura H, "Increased left atrial volume index predicts a poor prognosis in patients with heart failure", J Card Fail, 17, pp.210~216 (2011)
- Hense HW, "The associations of body size and body composition with left ventricular mass : impacts for indexation in adults", J Am Coll Cardiol, 32, pp.451~457 (1998)
- Writing Committee Members, "2013 ACCF", AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation, Circulation, pp.2013, 128[DOI]
- Ponikowski P, "2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association(HFA)of the ESC", Eur Heart J, 37, pp.2129~2200 (2016)
- Reis Filho JR, "Reverse cardiac remodeling : a marker of better prognosis in heart failure", Arq Bras Cardiol, 104, pp.502~506 (2015)